TABLE 1

Demographic, clinical, and laboratory characteristics of enrolled adult patients at baseline

CharacteristicaDatab for patients (n) in:
Nevirapine arm (21)Efavirenz arm (17)Total (38)
Age (yr)34 (24–48)33 (21–50)33 (21–50)
Male12 (57.1)10 (58.8)22 (57.9)
Wt (kg)52.6 (40.5–68.5)51.3 (39.1–72.3)51.9 (39.1–72.3)
BMI (kg/m2)19.1 (14.4–24.3)18.7 (16.7–20.0)18.9 (14.4–30.1)
Hemoglobin (g/dl)8.9 (7.0–10.5)9.3 (7.5–11.7)9.1 (7.0–11.7)
ALT (IU/liter)25.3 (7.7–124.2)32.3 (13.3–123.6)29.9 (7.7–124.2)
Total bilirubin (mg/dl)0.4 (0.2–2.2)0.5 (0.1–1.3)0.4 (0.1–2.2)
CD4 count (cells/mm3)108 (2–206)93 (18–214)104 (2–214)
Plasma HIV-1 RNA (log10 copies/ml)5.7 (4.2–7.0)5.4 (4.3–6.6)5.5 (4.2–7.0)
Active hepatitis B infection1/17 (5.9)4/17 (23.5)5/34 (14.7)
HCV infection0 (0.0)1 (5.9)1 (2.6)
Gastrointestinal symptoms1 (4.8)1 (5.9)2 (5.3)
Time between start of tuberculosis therapy and start of antiretroviral therapy (days)33 (28–40)33 (28–41)33 (28–41)
Pulmonary tuberculosis18 (85.7)10 (58.8)28 (73.7)
Pulmonary tuberculosis smear results
    Positive7 (33.3)8 (47.0)15 (39.5)
    Negative or missing results14 (66.7)9 (53.0)23 (60.5)
Cavitary disease1/18 (5.6)0/16 (0)1/34 (2.9)
  • a BMI, body mass index; ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus.

  • b Data are no. (%), median (range), or no. affected/no. tested (%).